The clinical features of PTC patients with RAI therapy, including age, gender, BRAF, tumor stage, lymph node stage, metastasis stage, and neoplastic disease stage were compared by the χ2 test between RAI-sensitive and RAI-refractory groups, which showed significant differences in tumor staging (P = 0.005) and neoplastic disease staging (P = 0.003). The gene discussed is BRAF; the disease is neoplasm.